Stock Events

Avinger 

$1.02
57
+$0.07+7.71% Friday 20:00

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
2.42M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-3.93
-2.76
-1.6
-0.43
Expected EPS
-2.03
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AVGR. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Boston Scientific
BSX
Mkt Cap120.45B
Boston Scientific Corporation competes with Avinger in the peripheral artery disease (PAD) treatment market, offering a range of interventional medical devices.
Abbott Laboratories
ABT
Mkt Cap197.08B
Abbott Laboratories offers vascular devices and competes in the same space as Avinger, particularly in treatments involving catheter-based technologies.
Medtronic
MDT
Mkt Cap113.61B
Medtronic plc provides medical devices for various conditions, including cardiovascular diseases, directly competing with Avinger's PAD treatment devices.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its subsidiary Cordis, competes in the cardiovascular and endovascular product market, overlapping with Avinger's offerings.
Integra Lifesciences
IART
Mkt Cap1.58B
Integra LifeSciences Holdings Corporation offers products for extremity surgery and reconstruction, competing with Avinger in the broader market for vascular health.
Sanara MedTech
SMTI
Mkt Cap313.93M
Sanuwave Health, Inc. focuses on the development of non-invasive therapies for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures, competing indirectly with Avinger's invasive PAD treatments.
Angiodynamic
ANGO
Mkt Cap309.32M
AngioDynamics, Inc. manufactures medical, surgical, and diagnostic devices, including those for vascular access, competing in the same market as Avinger.
Penumbra
PEN
Mkt Cap7.86B
Penumbra, Inc. offers innovative products focused on interventional therapies, including those for peripheral artery disease, making it a direct competitor to Avinger.
Baxter International
BAX
Mkt Cap19.36B
Baxter International Inc. provides a broad range of hospital and renal products, including products for vascular surgery, competing in the broader market relevant to Avinger's focus.

Analyst Ratings

5$Average Price Target
The highest estimate is $5.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and internationally. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. Further, the company develops IMAGE-BTK for the treatment of PAD lesions below-the-knee. It markets and sells its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was incorporated in 2007 and is headquartered in Redwood City, California.
Show more...
CEO
Jeffrey Soinski
Employees
71
Country
US
ISIN
US0537348858

Listings